116883-12-6

Basic information

• Product Name: BOC-LYS-AMC
• Synonyms: BOC-LYSINE-AMC;BOC-LYS-AMC;BOC-L-LYSINE 7-AMIDO-4-METHYLCOUMARIN;N-ALPHA-T-BUTOXYCARBONYL-L-LYSINE 7-AMIDO-4-METHYLCOUMARIN;Boc-Lys-AMC Acetate salt;Nalpha-Boc-L-lysine 7-amido-4-methylcoumarin;Boc-L-Lys-AMC;Nα-Boc-L-lysine 7-amido-4-methylcoumarin
• CAS NO: 116883-12-6
• Molecular Formula: C21H29N3O5
• Molecular Weight: 403.47
• Mol File: 116883-12-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: -15°C
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: BOC-LYS-AMC(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-LYS-AMC(116883-12-6)
• EPA Substance Registry System: BOC-LYS-AMC(116883-12-6)

Safety Data

• Hazardous Substances Data: 116883-12-6(Hazardous Substances Data)

Usage

Uses

Boc-L-Lys-Amc (cas# 116883-12-6) is a compound useful in organic synthesis.

Upstream product

• 97885-44-4 Boc-Lys(trifluoroacetyl)-AMC 
• 84624-27-1 Boc-Lys(Fmoc)-OH 
• 26093-31-2 7-amino-4-methylcoumarin. 
• 233691-67-3 N-(4-methyl-7-coumarinyl)-N-α-(tert-butyloxycarbonyl)-N-ω-acetyl-lysinamide 

Downstream Products

• 13734-28-6 Boc-Lys-OH 

Relevant articles and documents

Profiling of substrates for zinc-dependent lysine deacylase enzymes: HDAC3 exhibits decrotonylase activity in vitro

Systematic screening of the activities of the eleven human zinc-dependent lysine deacylases against a series of fluorogenic substrates (see scheme) as well as kinetic evaluation revealed substrates for screenings of histone deacetylases HDAC10 and HDAC11 at reasonably low enzyme concentrations. Furthermore, HDAC3 in complex with nuclear receptor corepressor 1 (HDAC3-NCoR1) was shown to harbor decrotonylase activity in vitro. Copyright

A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME

Embodiments of the present disclosure pertain to methods of selecting cyclic peptides that bind to a target by transforming a phage display library with a plurality of nucleic acids into bacterial host cells, where the nucleic acids include phage coat protein genes with a combinatorial region that encodes at least one cysteine and at least one non-canonical amino acid. The transformation results in the production of phage particles with phage coat proteins where the cysteine and the non-canonical amino acid couple to one another to form a cyclic peptide library. Phage particles are then screened against the desired target to select bound cyclic peptides. Amino acid sequences of the selected cyclic peptides are then identified. Additional embodiments pertain to methods of constructing a phage display library that encodes the cyclic peptides. Further embodiments of the present disclosure pertain to the produced cyclic peptides, phage display libraries and phage particles.

First non-radioactive assay for in vitro screening of histone deacetylase inhibitors

Inhibitors of histone deacetylase (HD) are of great potential as new drugs due to their ability to influence transcriptional regulation and to induce apoptosis or differentiation in cancer cells. So far only radioactive enzyme activity assays or in vivo a